RxDoctor Payments DataLook up a doctor →

Helen Reidler, PA

Medical · Baltimore, MDNPI 1639506553

Payments from drug & device makers

$9,980in general payments, 2019–2025

Across 367 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Johnson & Johnson$1K
  • Sumitomo Pharma America, Inc.$869
  • AstraZeneca$674
  • Astellas Pharma US Inc$591
  • Pfizer$519
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$6006%
  • Travel & lodging$1,40514%
  • Food & beverage$7,31573%
  • Education$6436%
  • Gifts$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,980 in reported general payments places this provider in the 95th percentile of 543 medical providers in Maryland.

See all medical providers in Maryland

Medicare billing

Part B allowed, 2024
$454,381
Medicare patients
897
Services billed
24,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron202$211,891
Abiraterone Acetate32$80,829
MyrbetriqMirabegron67$63,365
Methenamine Hippurate102$10,974
Tamsulosin Hcl238$4,691
Estradiol56$4,030
Cefdinir127$1,847
Fesoterodine Fumarate ErFesoterodine Fumarate16$1,474
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst92$1,214
Oxybutynin Chloride ErOxybutynin Chloride40$1,025
NitrofurantoinNitrofurantoin Macrocrystal23$721
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav74$710
Finasteride25$643
Ciprofloxacin Hcl95$479
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$869$211,891202 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$42$80,82932 claims
Astellas Pharma US IncMyrbetriq$591$63,36567 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 medical providers in Maryland.

Other medical in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →